publication date: Jan. 16, 2015
20150116 - Jan. 16, 2015
ISSUE 2 – JAN. 16, 2015PDF

Duke Scientist: I Hope NCI Doesn’t Get Original Data

In May 2008, the Blue Devils of genomic medicine were facing a mortal threat.

An NCI biostatistician was demanding the data Duke University scientists used to derive the predictors of response in ovarian cancer.

This inquiry had the potential to sink Duke’s technology that was purported to analyze tumors and use genomic insight to identify the optimal treatment for each patient. According to Duke’s projections, cancer treatment decisions are made 700,000 times a year in the U.S. alone.

Multiply that by $3,000—the going rate for advanced tests at that time—and you have $2.1 billion.

How the “Bad Luck” Cancer Paper Was Misread by the Press

How much of the potential to develop cancer is due to plain “bad luck”?

A paper published Jan. 1 in Science titled, “Variation in cancer risk among tissues can be explained by the number of cell divisions,” generated a mild controversy when the authors’ use of the term “bad luck” caught on in the press.

Conversation with The Cancer Letter
Kramer: Our Cancer Risk Is Not in the Stars

The stochastic process of stem cell divisions should not be equated with bad luck, said Barnett Kramer, director of the NCI Division of Cancer Prevention, focusing on misinterpretations of the “Bad Luck” paper by Cristian Tomasetti and Bert Vogelstein, of Johns Hopkins University School of Medicine.

AVEO Cuts Workforce by 66%, Ending Research Functions

AVEO Oncology announced plans to cut its workforce by two-thirds, end its internal research functions, and vacate up to 80 percent of its facilities, including laboratory and vivarium locations. The biotechnology company was co-founded by Ronald DePinho, president of MD Anderson Cancer Center.

The restructuring would leave about 20 full-time positions.

 

FASEB Offers Recommendations To Improve Research Funding

The Federation of American Societies for Experimental Biology called for a re-examination of the way research is funded in the U.S., in a report detailing the challenges facing researchers and the threats to continued progress in the field.

The report, Sustaining Discovery in Biological and Medical Science: A Framework for Discussion, presents a series of recommendations to alleviate them.

 

Obituary
Dorothy “Dottie” Thomas, 92, “Mother of Bone Marrow Transplantation”

Dorothy “Dottie” Thomas, wife and research partner to 1990 Nobel laureate E. Donnall Thomas, died Jan. 9, at her home near Seattle. She was 92. 

Don Thomas, pioneer of the bone marrow transplant and former director of the Clinical Research Division at Fred Hutchinson Cancer Research Center, preceded her in death on Oct. 20, 2012, also at age 92.

In Brief

  • MD Anderson’s Andrew Lee moves to Texas Center for Proton Therapy

  • A. Eugene Washington named chancellor for health affairs at Duke University

  • Julie Brahmer named director of thoracic oncology at Johns Hopkins Kimmel Cancer Center

  • Naiyer Rizvi named director of thoracic oncology at NewYork-Presbyterian/Columbia University Medical Center

  • Seton Hall University and Hackensack University Health Network to form four-year, private medical school

  • Roche acquires Bina Technologies Inc.

  • Karmanos Cancer Institute receives $5 million grant from the Dresner Foundation

  • ASCO and College of American Pathologists announce partnership

  • Mount Sinai Health System and Valley Health System announce collaboration

  • Pelotonia awards six grants to Ohio State

  • Genentech and Human Longevity Inc. announce multi-year agreement

  • MD Anderson, Intrexon, and Ziopharm announce sublicensing agreement with the University of Minnesota

  • Amgen and MD Anderson announce research agreement

Copyright (c) 2020 The Cancer Letter Inc.